Table 3.
Absolute risk (%) of model events.
| Strategy | DVT (symptomatic and asymptomatic) (95% CrI) | Non-fatal PE (95% CrI) | GI bleeding + ICH | SSB | Other major bleeding | CRNMB |
|---|---|---|---|---|---|---|
| eTHR | ||||||
| LMWH (std,std) + AES | 5.54% (%5.39 to %5.70) |
0.68% (%0.63 to %0.74) |
0.72% | 0.94% | 0.30% | 3.04% |
| LMWH (std,extd)+ AEs | 4.03% (%0.53 to %14.34) |
0.15% (%0.00 to %0.94) |
0.77% | 0.70% | 0.23% | 3.04% |
| Fondaparinux+ AES | 3.25% (%0.46 to %11.43) |
1.15% (%0.09 to %5.12) |
1.40% | 1.57% | 0.51% | 4.98% |
| Foot pump + AES | 14.66% (%1.99 to %46.06) |
1.48% (b) | 0.34% | 0.36% | 0.12% | 1.18% |
| IPCD | 33.06% (%5.56 to %76.99) |
5.28% (%0.15 to %31.35) |
0.34% | 0.36% | 0.12% | 1.18% |
| AES (above knee) | 8.30% (%0.87 to %48.85) |
10.21% (%0.00 to %88.30) |
0.34% | 0.36% | 0.12% | 1.18% |
| Foot pump | 28.01% (%2.41 to %78.81) |
21.94% (%0.11 to %98.05) |
0.34% | 0.36% | 0.12% | 1.18% |
| AES | 12.05% (%4.35 to %25.55) |
1.18% (%0.08 to %5.46) |
0.34% | 0.36% | 0.12% | 1.18% |
| LMWH (std,std) | 20.30% (%3.41 to %56.46) |
2.47% (%0.18 to %12.53) |
0.72% | 0.94% | 0.30% | 3.04% |
| LMWH (std,extd) | 9.76% (%0.97 to %36.66) |
0.45% (%0.00 to %3.19) |
0.77% | 0.70% | 0.23% | 3.04% |
| Aspirin (std duration) | 26.26% (%1.56 to %80.91) |
36.63% (%0.35 to %99.62) |
0.79% (c) | 1.03% | 0.33% | 3.29% |
| LMWH (std, std) + Aspirin (extd duration) | 0.05%(a) | 0.11% (%0.00 to %0.77) |
0.80% | 0.10% | 0.03% | 1.64% |
| Dabigatran | 18.91% (%2.05 to %60.30) |
3.56% (%0.13 to %20.41) |
1.19% | 1.34% | 0.43% | 3.48% |
| Apixaban | 9.81% (%0.55 to %43.30) |
2.01% (%0.05 to %12.24) |
1.17% | 1.16% | 0.37% | 2.75% |
| Rivaroxaban | 4.00% (%0.27 to %18.33) |
1.20% (%0.01 to %7.82) |
0.95% | 0.99% | 0.32% | 3.68% |
| No prophylaxis | 40.42% (%9.59 to %81.09) |
8.80% (%0.83 to %37.52) |
0.34% | 0.36% | 0.12% | 1.18% |
| eTKR | ||||||
| LMWH (std,std) + AES | 14.00% (%13.81 to %14.20) |
0.45% (%0.41 to %0.49) |
0.39% | 0.94% | 0.21% | 4.89% |
| Fondaparinux+ AES | 12.51% (%3.76 to %27.50) |
0.36% (d) | 4.20% | 5.85% | 1.34% | 25.11% |
| Foot pump + AES | 18.96% (%9.45 to %33.25) |
0.58% (d) | 0.36% | 0.88% | 0.19% | 4.58% |
| IPCD | 21.23% (%7.04 to %42.74) |
1.92% (%0.00 to %18.60) |
0.36% | 0.88% | 0.19% | 4.58% |
| Foot pump | 8.38% (%1.12 to %26.89) |
0.20% (d) | 0.36% | 0.88% | 0.19% | 4.58% |
| AES | 29.97% (%15.13 to %48.19) |
2.48% (%0.007 to %20.33) |
0.36% | 0.88% | 0.19% | 4.58% |
| LMWH (std,std) | 9.22% (%2.98 to %20.08) |
1.94% (%0.00 to %19.44) |
0.39% | 0.94% | 0.21% | 4.89% |
| LMWH (std,extd) | 7.83% (%1.80 to %20.51) |
0.87% (%0.000 to %6.25) |
0.43% | 0.14% | 0.03% | 6.77% |
| Aspirin | 15.28% (%3.64 to %37.46) |
0.43% (d) | 0.38% (e) | 0.93% | 0.21% | 4.84% |
| Dabigatran | 9.10% (%2.78 to %20.49) |
5.06% (%0.00 to %60.15) |
0.44% | 0.95% | 0.21% | 5.46% |
| Apixaban | 5.31% (%1.54 to %12.44) |
4.35% (%0.000 to %49.77) |
0.34% | 0.69% | 0.15% | 3.78% |
| Rivaroxaban | 4.32% (%1.17 to %10.42) |
1.45% (%0.00 to %13.84) |
0.64% | 1.33% | 0.29% | 5.83% |
| No prophylaxis | 34.21% (%13.98 to %58.93) |
4.47% (%0.002 to %46.25) |
0.42% | 0.88% | 0.19% | 4.58% |
AES, anti-embolism stockings; CrI, credible interval; CRNMB, clinically-relevant non-major bleeding; DVT, deep vein thrombosis; eTHR, elective total hip replacement; eTKR, elective total knee replacement; extd, extended; GI, gastrointestinal; ICH, intracranial hemorrhage; IPCD, intermittent pneumatic compressions device; LMWH, low molecular weight heparin; PE, pulmonary embolism; SSB: surgical site bleeding; std, standard.
a Not in DVT NMA. Point estimate calculated based on the assumption that the relative effectiveness for the PE outcome compared to LMWH (std,std) + AES will be the same for the DVT.
b Not in PE NMA. Point estimate calculated based on the assumption that the relative effectiveness for the DVT outcome compared to LMWH (std,std)+ AES will be the same for the PE.
c Source: Jameson 2011 (Hauck et al., 2017).
d Not in PE network. Point estimate calculated based on the assumption that the relative effectiveness for the DVT outcome compared to LMWH (std,std)+ AES will be the same for the PE.
e Source: Jameson 2012 (Arya et al., 2010).